Can United Therapeutics Outrun Amgen in the Next Rally?
Amgen surged 8.2% during the past Day. You may be tempted to buy more, or may want to reduce your exposure. But there is an entirely different perspective you might be missing. Is there a better alternative? Turns out, its peer United Therapeutics gives you more. United Therapeutics (UTHR) stock offers superior revenue growth across key periods, better profitability, and relatively lower valuation vs Amgen (AMGN) stock, suggesting you may be better off investing in UTHR
- UTHR’s Last 12 Months revenue growth was 13.5%, vs. AMGN’s 10.6%.
- In addition, its Last 3-Year Average revenue growth came in at 19.0%, ahead of AMGN’s 11.2%.
- UTHR leads on profitability over both periods – LTM margin of 48.7% and 3-year average of 49.1%.
These differences become even clearer when you look at the financials side by side. The table highlights how AMGN’s fundamentals stack up against those of UTHR on growth, margins, momentum, and valuation multiples.
Valuation & Performance Overview
| AMGN | UTHR | Preferred | |
|---|---|---|---|
| Valuation | |||
| P/EBIT Ratio | 22.7 | 13.9 | UTHR |
| Revenue Growth | |||
| Last Quarter | 9.0% | 6.8% | AMGN |
| Last 12 Months | 10.6% | 13.5% | UTHR |
| Last 3 Year Average | 11.2% | 19.0% | UTHR |
| Operating Margins | |||
| Last 12 Months | 24.1% | 48.7% | UTHR |
| Last 3 Year Average | 25.4% | 49.1% | UTHR |
| Momentum | |||
| Last 3 Year Return | 64.4% | 90.9% | UTHR |
Note: For “Last 3 Year Return” metric, preferred stock is one with higher returns unless the returns are too high (>300%) which creates risk of sell off.
See more revenue details: AMGN Revenue Comparison | UTHR Revenue Comparison
See more margin details: AMGN Operating Income Comparison | UTHR Operating Income Comparison
- This Strategy Pays You 10.0% While Lining Up LRCX at Bargain Prices
- Catalysts That Could Propel UnitedHealth Stock to the Moon
- What Could Go Wrong With Intel Stock?
- Cash Machine Trading Cheap – Docusign Stock Set to Run?
- Applied Materials Stock’s Winning Streak May Not Be Over Yet
- T-Mobile US Stock Now 21% Cheaper, Time To Buy
See detailed fundamentals on Buy or Sell UTHR Stock and Buy or Sell AMGN Stock. Below we compare market return and related metrics across years.
Historical Market Performance
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | Avg | Best | |
|---|---|---|---|---|---|---|---|---|---|
| Returns | |||||||||
| AMGN Return | 2% | 20% | 13% | -7% | 30% | 3% | 74% | ||
| UTHR Return | 42% | 29% | -21% | 60% | 38% | -2% | 215% | <=== | |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 1% | 84% | ||
| Monthly Win Rates [3] | |||||||||
| AMGN Win Rate | 33% | 58% | 58% | 50% | 50% | 50% | 50% | ||
| UTHR Win Rate | 67% | 42% | 42% | 58% | 50% | 50% | 51% | ||
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | 62% | <=== | |
| Max Drawdowns [4] | |||||||||
| AMGN Max Drawdown | -10% | -2% | -17% | -8% | -1% | -2% | -7% | <=== | |
| UTHR Max Drawdown | 0% | -23% | -26% | -4% | -22% | -5% | -13% | ||
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | -7% | ||
[1] Cumulative total returns since the beginning of 2021
[2] 2026 data is for the year up to 2/4/2026 (YTD)
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
No matter how good the numbers, stock investment is never a smooth ride. There is a risk you must factor in. Read UTHR Dip Buyer Analyses to see how the stock has fallen and recovered in the past.
Still not sure about AMGN or UTHR? Consider portfolio approach.
A Multi Asset Portfolio Beats Picking Stocks Alone
Stocks soar and sink but bonds commodities and other assets balance the ride. A multi asset portfolio keeps returns steadier and reduces single market risk.
The asset allocation framework of Trefis’ Boston-based, wealth management partner yielded positive returns during the 2008-09 period when the S&P lost more than 40%. Our partner’ strategy now includes Trefis High Quality Portfolio, which has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices